Platelet Rich Plasma Treatment for Chronic Achilles Tendinosis

Monto, Raymond Rocco

doi:10.3113/fai.2012.0379

Cited by 122 publications

(72 citation statements)

References 52 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Owens et al 47 reported modest improvement in functional outcome in 10 patients who had received PRP injection for mid substance Achilles tendinopathy. Monto et al 48 reported clinical success in 28 out of 30 patients with recalcitrant Achilles tendinosis. The improvement noted was in the AOFAS score and the MR architecture of the tendon.…”

Section: Discussionmentioning

confidence: 99%

Platelet-Rich Plasma Injections In The Management Of Chronic Tendinopathies

Swamy¹,

Mishra²,

Sadangi³

et al. 2017

IOSR JDMS

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Platelet-Rich Plasma Injections In The Management Of Chronic Tendinopathies

Swamy¹,

Mishra²,

Sadangi³

et al. 2017

IOSR JDMS

View full text Add to dashboard Cite

“…Over eight clinical human trials, the vast majority of patients suffering from chronic, recalcitrant tendinosis saw significant and substantial reductions in pain [88][89][90][91][92][93][94][95] and increases in joint function [72,88,90,[92][93][94][95] when treated with PRP without supplemental procedures. These patients had experienced symptoms of tendonosis for at least 3 months and had not responded to nonsurgical interventions [88][89][90][92][93][94][95]. Raymond Monto treated 30 patients experiencing severe, persistent Achilles tendinopathy with a single 4 mL injection of PRP [90].…”

Section: Prp For Chronic Tendinopathiesmentioning

confidence: 99%

“…These patients had experienced symptoms of tendonosis for at least 3 months and had not responded to nonsurgical interventions [88][89][90][92][93][94][95]. Raymond Monto treated 30 patients experiencing severe, persistent Achilles tendinopathy with a single 4 mL injection of PRP [90]. After 2 years, mean pain scores had improved dramatically.…”

Section: Prp For Chronic Tendinopathiesmentioning

confidence: 99%

Biologic and Tissue Engineering Strategies for Tendon Repair

Sigal

Grande

Dines

et al. 2016

Regen. Eng. Transl. Med.

View full text Add to dashboard Cite

This review summarizes recent developments in biologic treatments-including growth factors, platelet-rich plasma (PRP), stem cells, and cell-seeded scaffolds-for tendon repair. Growth and differentiation faction-5 (GDF-5), insulin-related growth factor-1 (IGF-1), and basic fibroblast growth factor (bFGF) all improved extracellular matrix (ECM) production and tensile strength of treated tendons; however, no clinical trials were done on GDF-5. Platelet-derived growth factor-BB (PDGF-BB) improved proliferation and ECM production, but did not consistently improve mechanical properties. The literature was mixed on the efficacy of PRP for the treatment of chronic and acute tendinopathies. However, PRP did cause any complications, and its benefits may be enhanced once an ideal, standardized composition is developed. Therefore, PRP may be a valid treatment, especially once nonsurgical management options have failed. Mesenchymal stem cells (MSCs) significantly and substantially improved the quality of tendon repairs and demonstrated the ability to regenerate an enthesis. Adipose-derived stem cells (ADSCs) have similar effects and are easier to harvest. The periosteum may also regenerate the tendon-bone attachment. Tenocytes, meanwhile, may be ideal for midsubstance tendon repairs. Cell-seeded scaffolds-especially ECMderived scaffolds-were demonstrated to improve ECM production, enhancing the healing abilities of tenocytes or stem cells while providing early mechanical support to healing tendons.Each of these treatments demonstrated enhanced healing compared to common surgical techniques; moreover, patient outcomes may be enhanced by combining these treatments. Lay SummaryTendon injuries are very prevalent and can be debilitating. Tendon heals poorly, and the scar tissue that forms is weak and susceptible to reinjury. A major focus of orthopedic research is regenerative medicine, encouraging the formation of healthy tendon rather than mechanically inferior scar tissue. This review summarizes the recent scientific literature on biologic treatments for tendon repair, such as growth factors, platelet-rich plasma, and stem cells. The purpose of which is to show which treatments are promising candidates for clinical use and research, helping to guide physicians and to lay out a path for future research.

show abstract

“…Several under powered studies have reported favorable results by the use of PRP for different tendon injuries [33][34][35][36][37][38][39][40] . Several well structured clinical randomized controlled trials [41][42][43][44][45][46][47][48][49][50][51][52][53] report no significant differences when PRP was compared to controls for the treatment of tendinopathy (elbow, achilles, rotator cuff, plantar fascia), rotator cuff and achilles tendon ruptures.…”

Section: Human Studiesmentioning

confidence: 99%

Growth factor delivery vehicles for tendon injuries: Mesenchymal stem cells and Platelet Rich Plasma

Guevara-Álvarez

Schmitt

Russell

et al. 2014

MLTJ

View full text Add to dashboard Cite

SummaryBackground: tendon tissue shows limited regeneration potential with formation of scar tissue and inferior mechanical properties. The capacity of several growth factors to improve the healing response and decrease scar formation is described in different preclinical studies. Besides the application of isolated growth factors, current research focuses on two further strategies to improve the healing response in tendon injuries: platelet rich plasma (PRP) and mesenchymal stem cells (MSCs). Objective: the present review focuses on these two options and describes their potential to improve tendon healing. Results: in vitro experiments and animal studies showed promising results for the use of PRP, however clinical controlled studies have shown a tendency of reduced pain related symptoms but no significant differences in overall clinical scores. On the other hand MSCs are not totally arrived in clinical use so that there is still a lack of randomized controlled trials. In basic research experiments they show an extraordinary paracrine activity, anti-inflammatory effect and the possibility to differentiate in tenocytes when different activating-factors are added. Conclusion: preclinical studies have shown promising results in improving tendon re-

show abstract

Platelet Rich Plasma Treatment for Chronic Achilles Tendinosis

Abstract: Platelet-rich plasma was used effectively to treat chronic recalcitrant cases of Achilles tendinosis.

Cited by 122 publications

References 52 publications

Platelet-Rich Plasma Injections In The Management Of Chronic Tendinopathies

Platelet-Rich Plasma Injections In The Management Of Chronic Tendinopathies

Biologic and Tissue Engineering Strategies for Tendon Repair

Growth factor delivery vehicles for tendon injuries: Mesenchymal stem cells and Platelet Rich Plasma

Contact Info

Product

Resources

About